Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EDAP
EDAP TMS SA
|
$15M | -$0.26 | -5.42% | -134.66% | $5.83 |
|
AKTX
Akari Therapeutics Plc
|
-- | -$0.11 | -- | -53.67% | $3.53 |
|
ASND
Ascendis Pharma A/S
|
$245M | -$0.18 | 54.04% | -76.86% | $262.82 |
|
CLLS
Cellectis SA
|
$9.6M | -$0.10 | -5.7% | -56.58% | $7.20 |
|
DBVT
DBV Technologies SA
|
$889.9K | -$0.34 | -- | -80.11% | $40.03 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EDAP
EDAP TMS SA
|
$2.97 | $5.83 | $111.1M | -- | $0.00 | 0% | 1.58x |
|
AKTX
Akari Therapeutics Plc
|
$0.27 | $3.53 | $9.6M | -- | $0.00 | 0% | -- |
|
ASND
Ascendis Pharma A/S
|
$212.84 | $262.82 | $13B | -- | $0.00 | 0% | 17.80x |
|
CLLS
Cellectis SA
|
$4.84 | $7.20 | $485.6M | -- | $0.00 | 0% | 6.02x |
|
DBVT
DBV Technologies SA
|
$19.03 | $40.03 | $520.7M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EDAP
EDAP TMS SA
|
24.46% | 0.744 | 10.36% | 0.94x |
|
AKTX
Akari Therapeutics Plc
|
8.54% | -2.620 | 6.43% | 0.16x |
|
ASND
Ascendis Pharma A/S
|
127.22% | -0.522 | 7.87% | 0.68x |
|
CLLS
Cellectis SA
|
54.27% | 0.665 | 41.7% | 1.35x |
|
DBVT
DBV Technologies SA
|
23.24% | -1.892 | 5.85% | 1.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EDAP
EDAP TMS SA
|
$7M | -$5.8M | -45.27% | -56.97% | -35.49% | -$5.2M |
|
AKTX
Akari Therapeutics Plc
|
-- | -$2.2M | -82.27% | -91.86% | -- | -$2.1M |
|
ASND
Ascendis Pharma A/S
|
$219.4M | $12.9M | -34.4% | -880.05% | 5.15% | $1.3M |
|
CLLS
Cellectis SA
|
$30M | $5.9M | -15.69% | -31.08% | 16.76% | -$4M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
Akari Therapeutics Plc has a net margin of -36.13% compared to EDAP TMS SA's net margin of --. EDAP TMS SA's return on equity of -56.97% beat Akari Therapeutics Plc's return on equity of -91.86%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
EDAP
EDAP TMS SA
|
43.02% | -$0.16 | $36.3M |
|
AKTX
Akari Therapeutics Plc
|
-- | -$0.19 | $24.8M |
EDAP TMS SA has a consensus price target of $5.83, signalling upside risk potential of 96.4%. On the other hand Akari Therapeutics Plc has an analysts' consensus of $3.53 which suggests that it could grow by 1340.41%. Given that Akari Therapeutics Plc has higher upside potential than EDAP TMS SA, analysts believe Akari Therapeutics Plc is more attractive than EDAP TMS SA.
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
EDAP
EDAP TMS SA
|
1 | 2 | 0 |
|
AKTX
Akari Therapeutics Plc
|
2 | 0 | 0 |
EDAP TMS SA has a beta of -0.152, which suggesting that the stock is 115.246% less volatile than S&P 500. In comparison Akari Therapeutics Plc has a beta of 0.279, suggesting its less volatile than the S&P 500 by 72.076%.
EDAP TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EDAP TMS SA pays -- of its earnings as a dividend. Akari Therapeutics Plc pays out -- of its earnings as a dividend.
EDAP TMS SA quarterly revenues are $16.2M, which are larger than Akari Therapeutics Plc quarterly revenues of --. EDAP TMS SA's net income of -$5.9M is higher than Akari Therapeutics Plc's net income of -$6.4M. Notably, EDAP TMS SA's price-to-earnings ratio is -- while Akari Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EDAP TMS SA is 1.58x versus -- for Akari Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
EDAP
EDAP TMS SA
|
1.58x | -- | $16.2M | -$5.9M |
|
AKTX
Akari Therapeutics Plc
|
-- | -- | -- | -$6.4M |
Ascendis Pharma A/S has a net margin of -36.13% compared to EDAP TMS SA's net margin of -28.55%. EDAP TMS SA's return on equity of -56.97% beat Ascendis Pharma A/S's return on equity of -880.05%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
EDAP
EDAP TMS SA
|
43.02% | -$0.16 | $36.3M |
|
ASND
Ascendis Pharma A/S
|
87.87% | -$1.17 | $751.5M |
EDAP TMS SA has a consensus price target of $5.83, signalling upside risk potential of 96.4%. On the other hand Ascendis Pharma A/S has an analysts' consensus of $262.82 which suggests that it could grow by 24.92%. Given that EDAP TMS SA has higher upside potential than Ascendis Pharma A/S, analysts believe EDAP TMS SA is more attractive than Ascendis Pharma A/S.
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
EDAP
EDAP TMS SA
|
1 | 2 | 0 |
|
ASND
Ascendis Pharma A/S
|
13 | 0 | 0 |
EDAP TMS SA has a beta of -0.152, which suggesting that the stock is 115.246% less volatile than S&P 500. In comparison Ascendis Pharma A/S has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.182%.
EDAP TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EDAP TMS SA pays -- of its earnings as a dividend. Ascendis Pharma A/S pays out -- of its earnings as a dividend.
EDAP TMS SA quarterly revenues are $16.2M, which are smaller than Ascendis Pharma A/S quarterly revenues of $249.6M. EDAP TMS SA's net income of -$5.9M is higher than Ascendis Pharma A/S's net income of -$71.3M. Notably, EDAP TMS SA's price-to-earnings ratio is -- while Ascendis Pharma A/S's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EDAP TMS SA is 1.58x versus 17.80x for Ascendis Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
EDAP
EDAP TMS SA
|
1.58x | -- | $16.2M | -$5.9M |
|
ASND
Ascendis Pharma A/S
|
17.80x | -- | $249.6M | -$71.3M |
Cellectis SA has a net margin of -36.13% compared to EDAP TMS SA's net margin of 1.68%. EDAP TMS SA's return on equity of -56.97% beat Cellectis SA's return on equity of -31.08%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
EDAP
EDAP TMS SA
|
43.02% | -$0.16 | $36.3M |
|
CLLS
Cellectis SA
|
85.76% | $0.01 | $219.7M |
EDAP TMS SA has a consensus price target of $5.83, signalling upside risk potential of 96.4%. On the other hand Cellectis SA has an analysts' consensus of $7.20 which suggests that it could grow by 48.76%. Given that EDAP TMS SA has higher upside potential than Cellectis SA, analysts believe EDAP TMS SA is more attractive than Cellectis SA.
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
EDAP
EDAP TMS SA
|
1 | 2 | 0 |
|
CLLS
Cellectis SA
|
2 | 2 | 0 |
EDAP TMS SA has a beta of -0.152, which suggesting that the stock is 115.246% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.784%.
EDAP TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EDAP TMS SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.
EDAP TMS SA quarterly revenues are $16.2M, which are smaller than Cellectis SA quarterly revenues of $35M. EDAP TMS SA's net income of -$5.9M is lower than Cellectis SA's net income of $586.4K. Notably, EDAP TMS SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EDAP TMS SA is 1.58x versus 6.02x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
EDAP
EDAP TMS SA
|
1.58x | -- | $16.2M | -$5.9M |
|
CLLS
Cellectis SA
|
6.02x | -- | $35M | $586.4K |
DBV Technologies SA has a net margin of -36.13% compared to EDAP TMS SA's net margin of --. EDAP TMS SA's return on equity of -56.97% beat DBV Technologies SA's return on equity of -280.59%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
EDAP
EDAP TMS SA
|
43.02% | -$0.16 | $36.3M |
|
DBVT
DBV Technologies SA
|
-- | -$1.21 | $68.9M |
EDAP TMS SA has a consensus price target of $5.83, signalling upside risk potential of 96.4%. On the other hand DBV Technologies SA has an analysts' consensus of $40.03 which suggests that it could grow by 109.38%. Given that DBV Technologies SA has higher upside potential than EDAP TMS SA, analysts believe DBV Technologies SA is more attractive than EDAP TMS SA.
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
EDAP
EDAP TMS SA
|
1 | 2 | 0 |
|
DBVT
DBV Technologies SA
|
4 | 0 | 1 |
EDAP TMS SA has a beta of -0.152, which suggesting that the stock is 115.246% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.
EDAP TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EDAP TMS SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
EDAP TMS SA quarterly revenues are $16.2M, which are larger than DBV Technologies SA quarterly revenues of --. EDAP TMS SA's net income of -$5.9M is higher than DBV Technologies SA's net income of -$33M. Notably, EDAP TMS SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EDAP TMS SA is 1.58x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
EDAP
EDAP TMS SA
|
1.58x | -- | $16.2M | -$5.9M |
|
DBVT
DBV Technologies SA
|
-- | -- | -- | -$33M |
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.